An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...